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A B S T R A C T
A hallmark of cancer cells is their ability to reprogram nutrient metabolism. Thus, disruption to this phenotype is
a potential avenue for anti-cancer therapy. Herein we used a phenotypic chemical library screening approach to
identify molecules that disrupted nutrient metabolism (by increasing cellular oxygen consumption rate) and
were toxic to cancer cells. From this screen we discovered a 1,4-Naphthoquinone (referred to as BH10) that is
toxic to a broad range of cancer cell types. BH10 has improved cancer-selective toxicity compared to doxor-
ubicin, 17-AAG, vitamin K3, and other known anti-cancer quinones. BH10 increases glucose oxidation via both
mitochondrial and pentose phosphate pathways, decreases glycolysis, lowers GSH:GSSG and NAPDH/NAPD+
ratios exclusively in cancer cells, and induces necrosis. BH10 targets mitochondrial redox defence as evidenced
by increased mitochondrial peroxiredoxin 3 oxidation and decreased mitochondrial aconitase activity, without
changes in markers of cytosolic or nuclear damage. Over-expression of mitochondria-targeted catalase protects
cells from BH10-mediated toxicity, while the thioredoxin reductase inhibitor auranoﬁn synergistically enhances
BH10-induced peroxiredoxin 3 oxidation and cytotoxicity. Overall, BH10 represents a 1,4-Naphthoquinone with
an improved cancer-selective cytotoxicity proﬁle via its mitochondrial speciﬁcity.
1. Introduction
The discovery of new anti-cancer agents has historically relied on
target-based drug screens [1]. However, phenotypic drug screens are
gaining renewed interest and are thought to identify drug leads/clinical
candidates more likely to possess therapeutically-relevant molecular
mechanisms of action [1]. Furthermore, phenotypic screens are proven
to outperform target-based approaches leading to FDA-approved ﬁrst-
in-class small molecule drugs [2]. It has been reported that many target-
based drug screens fail due to diverse biochemical mechanisms at the
target [2]. In contrast, phenotypic screens prioritise a biological eﬀect
over a mechanism of action and avoid some hurdles faced by target-
based models of drug discovery [1,2].
Most genetic aberrations that initiate and promote cancer
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development, such as oncogenic KRAS, BRAF, and MYC, activated Akt,
and loss of tumour suppressors (e.g. LKB1, PTEN, p53), in one way or
another impact cellular metabolism [3]. Not surprisingly, dysregulated
metabolism is now recognised as a ‘hallmark’ of cancer [4,5]. Although
reported many decades ago by Otto Warburg, the altered metabolism of
glucose by tumour cells remains an area of intense investigation and
potential avenue of drug discovery [6]. Increased glucose uptake and
ﬂux of glucose-derived carbons into lipids, nucleotides, and amino acids
facilitates cancer cell anabolic growth, proliferation, anti-oxidant de-
fence, metastasis, and immune system evasion, as reviewed [3]. How-
ever, it is not just metabolic pathways in the cytoplasm that provide
cancer cells with the ﬂexibility to thrive under diverse conditions.
Cancer cells can also utilise diﬀerent fuel sources through mitochon-
drial networks to aid tumour growth and progression [3]. Thus, the
intrinsic ability of cancer cells to use both glycolysis and mitochondrial
oxidative metabolism provides a selective advantage when exposed to
stressors including anti-cancer therapies and/or hypoxia, allowing
cancer cells to survive under these challenging conditions [7–9]. This
highlights the importance of targeting diverse metabolic pathways for
therapy to overcome the metabolic ﬂexibility of cancer cells.
With these factors in mind, we conducted a phenotypic screen to
identify small molecules that altered cell metabolism and were more
toxic to cancer cells than normal cells. Speciﬁcally, we describe a cell-
based phenotypic screen developed to detect small molecules that in-
crease cellular oxygen consumption rate (primary screen) and showed
greater toxicity to cancer cells than non-cancer cells (secondary screen).
Screening for molecules that increase oxygen consumption is a gain-of-
function screen that indicates increased nutrient oxidation and/or re-
active oxygen species (ROS) production, which are two prominent
mechanisms for disrupting cancer cell metabolism and viability
[10,11].
2. Materials and methods
2.1. 1 Cell culture
Human non-cancerous cells; skin (CCD-25SK, obtained from ATCC),
endometrium (hTERT-immortalised MAD11, from Dr Hui Li, University
of Virginia, USA), breast (MCF10A, obtained from ATCC), mesothelium
(MeT-5A, from Dr Glen Reid, University of Sydney, Australia), lung
ﬁbroblasts (WI-38, obtained from ATCC, MRC-5 from Dr. Joshua
McCarroll, Children's Cancer Institute, Australia). Human cancer cells;
mesothelioma (MSTO from Dr Glen Reid, Asbestos Disease Research
Institute, University of Sydney, Australia), endometrial cancer (ISHIK-
AWA, KLE, MFE-296, MFE-319, HEC1A, RL95-2 and AN3-CA were from
Dr Johnathan Lancaster, H. Lee Moﬃtt Cancer Centre and Research
Institute, Florida, USA), liver cancer (HepG2 and HuH7, obtained from
ATCC), colon cancer (HCT116 were obtained from ATCC, LIM2405,
LIM1215 and LIM1899 were from Dr Antony Burgess, Walter and Eliza
Hall Institute of Medical Research, Australia), ovarian cancer (SKOV-3
and A2780, obtained from ATCC), prostate cancer (LNCaP and PC3,
obtained from ATCC), breast cancer (MDA-MB-231 and MCF7, obtained
from ATCC), leukemia (K562, from Dr Maria Kavallaris, Children's
Cancer Institute, Australia), melanoma (SKMEL-2, A375, SKMEL-28 and
HT144, obtained from ATCC), lung cancer (CALU-1, from ATCC, and
H441, H1650, and H1975 were from Dr Joshua McCarroll, Children's
Cancer Institute, Australia). Primary murine hepatocytes were isolated
as described [12]. Mouse cancer cells; liver (Hepa-1c1c7, obtained from
ATCC) and melanoma (B16F1, from Dr Timothy Bullock, University of
Virginia, USA). Mouse 3T3-L1 cells over-expressing mitochondrial cat-
alase (or empty vector control) were a generous gift from Dr Daniel
Fazakerley (Charles Perkins Centre, Sydney University). All cell lines
were maintained as per instructions from the American Type Culture
Collection. Cells were passaged 2–3 times per week with trypsin/EDTA
and were kept in culture for a maximum of 4–5 weeks.
2.2. Chemicals
Chemicals were purchased from Sigma Aldrich or Cayman Chemical
(Ann Arbor, Michigan USA), and were prepared in DMSO, sterile water,
or PBS, and stored at appropriate temperatures, following manufac-
turer's instructions. BH10 was ﬁrst purchased from TimTec (Newark,
DE) and then synthesized by Dr Naresh Kumar as described in Section
2.14 below (UNSW, Sydney, Australia).
2.3. Chemical library screen
The ApexScreen 5040 small molecule diversity library was pur-
chased from TimTec (Newark, DE) and compounds were screened for
alterations in cellular O2 consumption using 96-well Becton Dickinson
(BD) Oxygen Biosensor (OBS) microplates (Bedford, MA). Molecules
were screened at a concentration of 5 μg/mL (TimTec Apex Screen) in
rat L6 myoblasts, as described previously [13]. Hits were identiﬁed as
those that increased O2 consumption over vehicle (DMSO) control.
2.4. Cytotoxicity assays
Cells (2500–5000/well) were seeded in 96-well plates and in-
cubated at 37 °C overnight prior to drug treatment. Drugs diluted in cell
culture medium were added to each well at the indicated concentra-
tions. Cell viability was determined 48 h later by addition of thiazolyl
blue tetrazolium bromide (MTT) reagent (3 h). Formazan crystals were
solubilized in solvent (4 mM HCl, 0.1% NP-40 in isopropanol) and ab-
sorbance read at 590/620 nm using an EnSight Multimode plate reader
(PerkinElmer). Viability of drug-treated cells is displayed as a percen-
tage of control cells i.e. cells with equivalent concentrations of the
appropriate vehicle. Synergy calculations were conducted according to
the methods outlined by Chou and Talalay [14], using a non-constant
drug ratio. Data were analysed in Compusyn (Combosyn, Inc.) whereby
combination index (CI) values less than 1 indicate drug synergy.
2.5. Cell death assays
Cell death was measured using the Muse® Annexin V and Dead Cell
Assay kit (Merck), according to manufacturer's instructions. Brieﬂy,
HEC1A cells were seeded in 6-well plates (100,000/well) and the next
day treated for 22 h with BH10 (20 μM ﬁnal), 3-BP (10mM ﬁnal, pre-
pared in PBS and neutralised to pH 7.4), or vehicle (DMSO). Cells on a
separate plate were exposed to UV irradiation (150,000 μJ/cm2). Non-
attached and attached cells were harvested, centrifuged at 300×g for
5min, and cell pellets resuspended in phenol red-free DMEM supple-
mented with 25mM glucose, 4 mM L-glutamine, 1 mM sodium pyr-
uvate, 1.5 g/L sodium bicarbonate and 1% FBS (2–3 x 105 cells/mL).
Cells were diluted 1:1 with Muse reagent, incubated for 5min at room
temperature, and then run on the Muse™ Cell Analyzer (2000 counts/
sample). Caspase activity was measured using Caspase-Glo® 3/7 assay
reagent (Promega). HEC1A cells were seeded in 96-well plates at
5000 cells/well and treated for 6–22 h with BH10 (20 μM ﬁnal) or ve-
hicle (DMSO) prepared in media, or UV-irradiated in the presence or
absence Q-VD-OPh hydrate (50 μM ﬁnal, Merck). Caspase Glo® reagent
was added to cells (1:1 ratio) and the lysed cell solution transferred to a
white 96-well plate. Luminescent signal was detected using an EnSight
Multimode plate reader (PerkinElmer).
2.6. Western blotting
Protein lysates (5–20 μg) were resolved on Any kD™ Mini-Protean
TGX Precast gels (Bio-Rad) and electro-transferred to nitrocellulose
membrane. Proteins were detected with rabbit antibodies; PARP (Cell
Signalling), PRDX2, catalase (Abcam), PRDX3 (AbFrontier), and a
mouse antibody; 14-3-3 (Santa Cruz). Primary antibodies were detected
with donkey anti-mouse IgG (AlexaFluor790) or anti-rabbit IgG
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(AlexaFluor680) (Abcam) and membranes scanned on the LI-COR
ODYSSEY System (LI-COR, Lincoln, NE, USA). For PRDX blotting;
MAD11 (1×105/well) and HEC1A (2×105/well) cells were seeded in
6 well plates a day prior to drug treatments. Cells were treated with
media or GSH (2 mM, pH neutralised) for 15 min prior to adding ve-
hicle (DMSO), BH10, vitamin K3, auranoﬁn, or BH10 + auranoﬁn for
150 min. Cells were then rinsed and incubated with ice-cold catalase-
treated PBS (1 mL/well) containing 100 mM NEM for 10 min on ice.
Catalase-treated PBS was prepared by adding 5 μL pre-warmed (37 °C
for 30min) bovine catalase solution to 2.89mL 50mM pre-warmed
potassium phosphate buﬀer ( ~1000 units/mL bovine catalase). This
solution was diluted 1:10 into warm PBS (~100 units/mL) and in-
cubated at 37 °C for another hour to remove H2O2. Following catalase
treatment, cells were lysed in HES-SDS buﬀer [250mM Sucrose, 20mM
HEPES (pH 7.4), 2% SDS (w/v), 1 mM EDTA] containing 100mM NEM.
Cell lysates were diluted with sample buﬀer without a reducing agent
and run on gels according to methods described in manuscript.
Densitometry was used to calculate the ratio of PRDX dimer to
monomer for each condition.
2.7. Metabolomics
HEC1A cells were seeded in 15 cm dishes at 8 million cells per dish,
with 4 replicate plates per treatment per time point. Scaling to 15 cm
dishes with less volume per cell number required us to use 50 μM BH10
to kill > 80% of cells at 24 h. Therefore, the metabolomics studies were
performed with 50 μM BH10 and equivalent volumes of vehicle
(DMSO). Cells were incubated for 5, 30, 90 and 150min and then rinsed
twice with ice-cold PBS. Cells were then scraped in ice-cold PBS and
pelleted by centrifugation at 2000 rpm at 4 °C. PBS was removed, then
cell pellets were frozen on dry ice and stored at −80 °C until shipment
to Metabolon Inc. (Durham, NC, USA). An equivalent amount of ma-
terial for each sample was extracted and run across the DiscoveryHD4™
global proﬁling platform. A recovery standard was added prior to the
ﬁrst step in the extraction process for QC purposes. Proteins were
precipitated with methanol under vigorous shaking for 2min (Glen
Mills GenoGrinder 2000) followed by centrifugation. The resulting ex-
tract was divided into ﬁve fractions: one for analysis by UPLC-MS/MS
with positive ion mode electrospray ionization, one for analysis by
UPLC-MS/MS with negative ion mode electrospray ionization, one for
LC polar platform, one for analysis by GC-MS, and one sample was
reserved for backup. Samples were placed brieﬂy on a TurboVap®
(Zymark) to remove the organic solvent. For LC, the samples were
stored overnight under nitrogen before preparation for analysis. For GC,
each sample was dried under vacuum overnight before preparation for
analysis. Raw data was extracted, peak-identiﬁed (using area-under-
the-curve) and QC processed using Metabolon's hardware and software.
Compounds were identiﬁed by comparison to library entries of puriﬁed
standards or recurrent unknown entities. Overall, a total of 373 com-
pounds of known identity (named biochemicals) were identiﬁed and
analysed.
2.8. 14C- and 3H- tracer experiments
Sub-conﬂuent cells were incubated in Krebs Ringer Phosphate (KRP)
solution (120mM NaCl, 600 μM Na2HPO4, 400 μM NaH2PO4, 6mM
KCl, 1.2mM MgSO4, 12.5mM HEPES pH 7.4, 1 mM CaCl2) with 20 μM
BH10 or vehicle (DMSO) with nutrients, (5mM glucose, 500 μM glu-
tamine, 125 μM palmitate, 50 μM acetate, 1 mM L-carnitine, 0.25% fatty
acid-free BSA) containing either 10 μCi/mL D-[3-3H]glucose, 5 μCi/mL
D-[14C(U)] glucose, 5 μCi/mL D-[14C(1)] glucose, 5 μCi/mL D-[14C(6)]
glucose, 1 μCi/mL L[14C(U)]-glutamic acid, or 2 μCi/mL[1–14C]-pal-
mitic acid for 90min in sealed wells. Substrate oxidation was measured
by adding 2M HClO4 (to halt the reaction) and evolved 14C–CO2 was
captured in PCR tubes with 50 μL 1M NaOH, and then transferred to
scintillation vials. For measurements of glycolysis, reactions were
stopped with 1 N HCl, and D-[3-3H] glucose was separated from tri-
tiated [3H]2O (generated from dehydration at enolase in glycolytic re-
action) by diﬀusion. Samples were counted using a LS 6500 Multi-
purpose Scintillation Counter (Beckman Coulter) and substrate meta-
bolism for each sample (pmol of substrate disintegrated per minute)
normalised to protein content per well.
2.9. 13C-glucose tracer experiments
Polar metabolites were extracted from cells using a methanol-water-
chloroform method [15]. HEC1A cells were seeded at 5× 105/well in
6-well plates and treated with vehicle (DMSO) or BH10 (50 μM) for
90min (isotopic steady-state was reached at this time point in labelled
medium). Cells were washed and quenched using ice-cold isotonic
(0.9% w/v) NaCl, and then scraped in 5mL of 1:1 methanol: water
solution at −30 °C. 1 nM of internal standard (chlorophenylalanine)
was added to each well. Cell slurry was transferred to Falcon tubes
containing 5mL chloroform at −30 °C. Liquid-liquid extraction was
performed by vortexing brieﬂy and centrifuging at maximum speed for
10min. The top aqueous phase was transferred into glass tubes and
liquid evaporated without heat by SpeedVac (Savant). Dried samples
were promptly derivatised by TBDMS-silylation method and analysed
by GC-MS [16]. Isotopologue abundances have been corrected for
natural enrichment.
2.10. Seahorse ﬂux analysis
Cells (8000 cells MAD11/well and 15,000 HEC1A cells/well) were
seeded in 96-well Seahorse tissue culture plates. The next day, cells
were rinsed twice with PBS prior to addition of Seahorse media (160
μL/well) and then placed in a non-CO2 incubator at 37 °C for 1 h.
Seahorse media contained phenol red-free DMEM (Sigma), 25mM
glucose, 4 mM L-glutamine and 1mM sodium pyruvate (pH 7.4, ﬁlter
sterilized). BH10 and vehicle (DMSO) were prepared in media (10x
concentration) and loaded into port A. For thiol compound experi-
ments, NAC and GSH were prepared at 20mM (10x concentration) in
Seahorse media, neutralised to pH 7.4, and loaded into port B. Basal
OCR (pmoles O2/min) was measured using the Seahorse XFe96 Flux
Analyzer (Seahorse Biosciences, North Billerica, MA). OCR rates were
averaged over a minimum of 5 wells/plate/treatment condition and 3
independent plates and normalised to protein content per well.
2.11. NADPH and GSH assays
An NADP/NADPH-Glo assay (Promega) was used to measure
NADPH/NADP+ levels, according to manufacturer's instructions.
Brieﬂy, cells were seeded in 6-well plates (1×105/well for MAD11 and
2×105/well for HEC1A) and treated for 2.5 h with BH10 (20 μM) or
equivalent volumes of vehicle control (DMSO). Media was removed
from wells prior to adding equal volumes (60 μL) of PBS then 1% do-
decyltrimethylammonium bromide in 0.2 N NaOH. The remainder of
the assay followed the protocol supplied with the kit. Luminescent
signal was detected using an EnSight Multimode plate reader
(PerkinElmer). GSH:GSSG ratios were measured using the Glutathione
(GSH/GSSG/Total) Fluorometric Assay Kit (Biovision, K264). Cells
were seeded in 10 cm dishes (1×106 for MAD11 and 2× 106 for
HEC1A) in 10mL media. The following day, cells were treated with
BH10 (20 μM) or equivalent volumes of vehicle (DMSO) for 2.5 h. Cells
were rinsed with ice-cold PBS and then scraped from the dish in 800 μL
ice-cold PBS. Cells were spun at 5000 rpm for 3min at 4 °C, cell pellets
resuspended in 100 μL glutathione assay buﬀer, and ice-cold perchloric
acid (20 μL) was added to each sample (60 μL). GSH and GSSG levels
were then measured according to manufacturer's instructions.
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2.12. Aconitase assay
HEC1A cells were seeded and treated with vehicle or BH10 as per
GSH assays. Mitochondrial fractions were extracted using a Cell
Fractionation Kit (Abcam, ab109719) from cells pellets resuspended in
80 μL buﬀer A. Mitochondrial aconitase activity was measured using
the Aconitase Enzyme Activity Microplate assay (Abcam, ab109712).
Samples were diluted to 0.45mg/mL (protein conc.), and 55 μL of each
were added to 5 μL aconitase solution. Absorbance was read at
240 nm at multiple time points and the rate of enzyme activity was
calculated in OD/min.
2.13. Oxidative DNA damage ELISA
Cells were seeded in 6-well plates (1×105/well MAD11 and
2×105/well HEC1A) and treated for 6 h with BH10 or vitamin K3
(20 μM) or equivalent volumes of vehicle (DMSO). Non-attached and
attached cells were harvested, centrifuged at 300×g for 5min, and
pellets collected for DNA extraction using the GenElute Mammalian
genomic DNA miniprep kit (Sigma). DNA was then concentrated by
ethanol precipitation and DNA (3 μg in 20 μL) was then denatured by
adding 2 μL of 0.5M sodium acetate (pH 5.1), 0.2 μL of 1M MgCl2 and
heating samples to 100 °C for 5min. Samples were cooled on ice (5min)
before adding Nuclease P1 (0.375 μL of 40 ng/μL stock, Sigma N8630)
and heating at 50 °C for 1 h pH was adjusted to 7.5–8.5 with 1M Tris
(0.25 μL of 1M Tris pH 10.5). Alkaline phosphatase (Sigma) was added
to each sample (0.03U per 3 μg DNA) before heating to 37 °C for 30min
followed by 100 °C for 10min. Samples were diluted to 0.04 ng/μL
using buﬀer from the GenElute kit and placed on ice. Samples (equiv. of
2 μg DNA in 50 μL) were analysed using the DNA/RNA Oxidative
Damage ELISA kit (Cayman Chemical), according to manufacturer's
instructions.
2.14. Synthesis of BH10
BH10 was synthesized by a method modiﬁed from Brun et al. [17].
The appropriate naphthoquinone (1 equivalent) was dissolved in ap-
propriate solvent (20mL) and to the resulting mixture were added 1
equivalent of appropriate amine and 1 equivalent of Et3N. The resulting
mixture was stirred at room temperature for 17–72 h. The resulting
mixture was concentrated in vacuo, diluted in EtOAc and washed with
water before the organic layer was dried over anhydrous Na2SO4. The
solvent was evaporated, and the resulting residue was puriﬁed via ﬂash
column chromatography (when required) in the appropriate solvent
system to aﬀord the product. The general synthetic scheme was; 2,3-
dichloro-[1,4]-naphthoquinone (0.51 g, 2.20mM), Et2O (20mL), 4-(2-
aminoethyl)morpholine (0.30mL, 2.20mM), Et3N (0.31 mL, 2.20mM).
Reaction stirred for 18 h. Product eluted with EtOAc/n-hexane= 3:1 to
aﬀord a dark orange powder 1 (0.63 g, 89%): mp: 110–112 °C; 1H NMR
(300MHz, CDCl3): δ 8.15 (d, J=9.0 Hz, 1H), 8.03 (d, J= 9.5 Hz, 1H),
7.75 (dd, J=7.5 Hz, 1H), 7.65 (dd, J=7.6 Hz, 1H), 6.88 (br s, 1H),
3.98 (dd, J=17.1 Hz, 2H), 3.78 (t, J= 9.1 Hz, 4H), 2.71 (t,
J=11.0 Hz, 2H), 2.55 (t, J=8.8 Hz, 4H); 13C NMR (CDCl3): δ 180.70,
176.80, 144.81, 135.03, 132.68, 132.51, 130.31, 126.92, 126.88,
67.03, 57.80, 53.20, 40.81.
2.15. Statistical analyses
Data with normal distributions were analysed using parametric tests
and data with unequal variances were analysed using non-parametric
tests (indicated within ﬁgure legends). All statistical analyses were
performed in GraphPad Prism with the exception of the metabolomics
experiments where following normalization to Bradford protein con-
centration, log transformation and imputation of missing values, if any,
with the minimum observed value for each compound, Welch's two-
sample t-test was used to identify biochemicals that diﬀered
signiﬁcantly between experimental groups.
3. Results
3.1. Phenotypic screen to identify modulators of oxidative metabolism
Herein we repurposed a diversity chemical library screen for cel-
lular oxygen consumption rate (OCR), as described [13]. From a total of
5040 compounds screened, we selected the top 25 hits that increased
OCR for secondary screening in a small panel of 3 cancer and 3 non-
cancerous cells from skin, lung, and endometrium (Fig. 1A). Hit number
10 (2-chloro-3-[(2-morpholin-4-ylethyl)amino]naphthalene-1,4-dione),
referred to as BH10 (Fig. 1B), had the best cancer-selective toxicity in
this panel of cells and outperformed benchmarking to a control com-
pound, piperlongumine, that is reported to have exceptional selectivity
for killing cancer cells over non-cancer cells in a panel of 13 cancer cell
lines and 6 non-cancer lines [18] (Fig. 1C–D) and works by inhibiting
glutathione S-transferase pi 1 to induce oxidative stress [18].
To better understand the anti-cancer properties of BH10, we
screened BH10 across a much larger panel of 39 non-cancerous and
cancer cells from diﬀerent tissues of origin (Fig. 1E). The mean IC50
values for each cell (calculated from dose response curves) are shown in
Fig. 1E (as listed in Supp. Table 1). From this screen we identiﬁed cells
that were resistant and sensitive to BH10. Of the non-cancerous cells, 6
of 8 had IC50 values greater than 30 μM, whereas 19 of the 31 cancer
cells had IC50 values less than 15 μM (Supp. Table 1).
Fig. 1. Phenotypic drug screen identiﬁes small molecule with better
cancer cell-speciﬁc toxicity than piperlongumine. (A) Schematic overview
of drug screen. (B) Chemical structure of BH10. Viability of cells (%, normalised
to vehicle control) exposed to increasing doses of BH10 (C) and piperlongumine
(D) for 48 h. Panel of non-cancerous and cancer cell lines are shown on the left.
(E) Mean IC50 values for cells treated with BH10 for 48 h (IC50 values were
calculated from dose response curves). Non-cancerous cells are displayed with
blue bars and cancer cells are displayed with red bars. See Supp. Table 1 for IC50
values. n≥ 3 for all experiments. Data represent mean ± SEM. (For inter-
pretation of the references to colour in this ﬁgure legend, the reader is referred
to the Web version of this article.)
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3.2. BH10 has improved cancer-selective toxicity than other quinones and
molecules that disrupt glucose metabolism
Quinones are an important class of anti-cancer molecules that have
been used in the clinic for decades [19]. We therefore investigated
whether BH10, which is a 1,4-naphthoquinone, had a diﬀerent cyto-
toxicity proﬁle than other quinones (Fig. 2). The HEC1A endometrial
cancer cell line and the non-cancerous MAD11 endometrial cell line
were tested for viability in response to a panel of known anti-cancer
quinones and only BH10 showed selective toxicity towards the cancer
cells (Fig. 2A) (see Supp. Table 2 for IC50 values). In contrast, the
quinone molecules CDC25 phosphatase inhibitor II (Fig. 2B), vitamin
K3 (Fig. 2C), doxorubicin (Fig. 2D), mitomycin C (Fig. 2E), β-lapachone
(Fig. 2F), 17-AAG (Fig. 2G), and streptonigrin (Fig. 2H) did not show
cancer-selective toxicity (see Supp. Table 2 for IC50 values). Di-
chloroacetate (DCA) was tested because it is thought to increase mi-
tochondrial glucose oxidation by relieving pyruvate dehydrogenase
kinase's inhibition of pyruvate dehydrogenase [20]; however, DCA was
equally toxic to HEC1A and MAD11 cells and required high millimolar
doses (Fig. 2I). Vitamin C was tested because it is shown to induce ROS,
deplete glutathione, and target GAPDH [21]; however, Vitamin C had
similar toxicity to HEC1A and MAD11 cells (Fig. 2J) (see Supp. Table 2
for IC50 values). Overall, these results indicate that BH10 has a distinct
mechanism of action compared to other anti-cancer quinones or mo-
lecules that disrupt redox control and glucose metabolism.
3.3. BH10 induces necrosis in cancer cells
We next sought to determine how BH10 induced cancer cell death.
Flow cytometry analyses showed that BH10 signiﬁcantly increased the
percentage of HEC1A cells in late apoptosis/necrosis (Fig. 3A–B). Ul-
traviolet radiation (UV) and 3-bromopyruvate (3-BP) were used as
positive controls for apoptosis and necrosis, respectively [22]. UV
treatment induced a signiﬁcant increase in caspase 3/7 activity at 6 and
22 h, which was inhibited by the pan-caspase inhibitor Q-VD-OPH
(QVD) (Fig. 3C). In contrast, BH10 did not increase caspase activity at
either time point (Fig. 3C). UV treatment also induced PARP cleavage in
HEC1A cells, while BH10 did not (Fig. 3D). Further analyses revealed
that BH10-induced cancer cell death was not rescued by the necroptosis
inhibitors necrostatin (RIPK1 inhibitor) or necrosulfanomide (MLKL
inhibitor), the ferroptosis inhibitor ferrostatin, and BH10-induced cell
death was also not altered by the PARP inhibitor, olaparib (not shown).
These data support a mechanism for BH10-induced cancer cell death
via necrosis.
3.4. BH10 disrupts glucose, glutathione, nicotinamide, and mitochondrial
metabolism
To expand our understanding of how BH10 inﬂuences cellular me-
tabolism, metabolomics analyses were performed on HEC1A cancer
cells treated with BH10 or vehicle control (DMSO) for 5, 30, 90 and
150min (Table 1). Results showed that BH10 treatment disrupted
Fig. 2. BH10 shows improved cancer cell-selective toxicity compared to
other anti-cancer quinones and molecules that disrupt glucose metabo-
lism. Non-cancerous MAD11 (blue lines) and cancerous HEC1A cells (red lines)
were exposed to increasing doses of (A) BH10, (B) CDC25 phosphatase inhibitor
II, (C) vitamin K3, (D) doxorubicin, (E) mitomycin C, (F) β-lapachone, (G) 17-
AAG, (H) streptonigrin, (I) dichloroacetate (DCA), and (J) vitamin C, for 48 h.
Cell viability is shown as a percentage normalised to vehicle-treated cells. Each
compound structure is shown with corresponding graphs. n≥ 3 for all ex-
periments. Data represent mean ± SEM. Statistical analyses comparing the
IC50 values of MAD11 vs HEC1A for each drug are shown in Supp. Table 2. (For
interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the Web version of this article.)
Fig. 3. BH10 induces necrosis in cancer cells. (A) Representative ﬂow cy-
tometry graphs from HEC1A cells treated with vehicle (DMSO), BH10 (20 μM),
3-bromopyruvate (3-BP, 10mM), or UV-irradiated (22 h post treatment). (B)
Quantiﬁcation of ﬂow cytometry data for the aforementioned conditions. (C)
Caspase 3/7 activity in HEC1A cells following treatment with vehicle (DMSO),
BH10 (20 μM), or UV-irradiation [(+/− the pan-caspase inhibitor, Q-VD-OPh
hydrate (QVD)] (6 and 22 h post treatment). (D) Representative western blot of
PARP (and cleaved PARP) protein in HEC1A cells treated with vehicle (DMSO),
BH10 (20 μM), or UV-irradiated (6 h post treatment). 14-3-3 serves as a protein
loading control. n ≥ 3 for all experiments. Data were analysed by 2-way
ANOVA with Dunnet's multiple comparison test (B) and Kruskal-Wallis with
uncorrected Dunn's test (C), where alpha = 0.05, ***p ≤ 0.001,
****p ≤ 0.0001. For B and C data represent mean ± SEM.
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glucose metabolism by decreasing several glycolytic intermediates that
are metabolised downstream of phosphofructokinase, including lactate
(Table 1). An increase in pentose phosphate pathway (PPP) inter-
mediates, as well as 5-carbon sugar alcohols (ribose, ribitol, and ara-
bitol/xylitol) were observed in cells treated with BH10 with accumu-
lation increasing with time (Table 1). In addition, several activated
nucleotide sugars (e.g., UDP-glucose, UDP-galactose) were decreased in
BH10-treated cells at the later time points of 90 and 150min (Table 1).
Alterations in glutathione biosynthesis and degradation/recycling
pathways were also observed in BH10-treated cells (Table 1). GSH was
signiﬁcantly lower (≥10% decrease) in BH10-treated cells from 30 to
150min, with a brief but signiﬁcant elevation in oxidized glutathione
(GSSG) observed at 5min (22% increase) (Table 1). A decline in GSH
levels may be attributed to decreased synthesis, as accumulation of the
amino acid precursor methionine, along with decreased availability of
the rate-limiting biochemical for glutathione synthesis, cysteine, were
observed in BH10-treated cells (Table 1). Pronounced elevations in
ophthalamate, a glutathione-like biochemical that is synthesized by the
same enzymes [gamma-glutamylcysteine synthetase (GCS) and glu-
tathione synthetase (GS)] as glutathione, but with 2-aminobutyrate in
place of cysteine, were observed in BH10-treated cells from 30 to
150min (Table 1). These data suggest continued activity of glutathione
synthetic machinery despite limited cysteine availability.
BH10-induced changes in glucose utilization also translated to al-
terations in tricarboxylic acid (TCA) cycle intermediates (Table 1).
Accumulation of citrate was consistently observed after the 30-min time
point and was the most-increased metabolite in BH10-treated cells
(6.54-fold increase in BH10 vs vehicle-treated controls at 150min,
p < 0.05). Signiﬁcant decreases in nicotinamide metabolites (nicoti-
namide and nicotinamide adenine dinucleotide, NAD+) were also ob-
served while ADP-ribose was the most decreased metabolite (97% de-
crease in BH10 vs vehicle-treated controls at 150min, p < 0.05)
(Table 1).
Using radiolabelled metabolic tracers, we conﬁrmed that BH10
decreased glycolysis by 37% (p=0.015, Fig. 4A) and increased glucose
oxidation by 8-fold in HEC1A cancer cells (p= 0.022, Fig. 4B). In
Table 1
Metabolites altered in BH10-treated HEC1A cells. Metabolomics analysis of HEC1A cells treated with BH10 or vehicle control for the indicated time points. Dark
red boxes indicate metabolites with mean values signiﬁcantly increased in BH10-treated cells (p≤ 0.05, fold change of ≥1.00), dark green boxes indicate meta-
bolites with mean values signiﬁcantly decreased in BH10-treated cells (p≤ 0.05, fold change of< 1.00), light green boxes indicate metabolites with mean values
approaching signiﬁcant decreases (0.05 < p < 0.1, fold change < 1.00), n= 4 for all time points. Replicate values for each metabolite and standard deviations for
both BH10 and vehicle control, at each time point, are provided in Supp File 1.
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contrast, the oxidation of palmitate and glutamine were not sig-
niﬁcantly altered by BH10 (Fig. 4C–D). To distinguish mitochondrial
glucose oxidation from pentose phosphate pathway (PPP) oxidation, we
used 1–14C and 6–14C glucose tracers. 1-14C-glucose can be metabolised
to 14CO2 in either the cytosol (via the PPP) or mitochondria (Fig. 4E),
whereas 14CO2 released from 6-14C-glucose only occurs in mitochondria
(Fig. 4F). Results show that BH10 treatment signiﬁcantly increased CO2
generation from 1-14C-glucose in both non-cancerous MAD11 cells and
cancerous HEC1A cells (p < 0.05, Fig. 4E). The eﬀect of BH10 was
greater in the HEC1A cells (15-fold increase, p < 0.0001) compared
with MAD11 cells (2.7-fold increase, p= 0.019) (Fig. 4E). In contrast,
BH10 treatment only increased CO2 generation from 6-14C-glucose in
cancerous HEC1A cells (2.4-fold increase, p < 0.05, Fig. 4F). Mea-
surements of PPP ﬂux (obtained by subtracting values of 6–14C-glucose
from 1-14C-glucose) showed that BH10 signiﬁcantly increased ﬂux of
glucose to this pathway in MAD11 cells (2.7-fold increase, p= 0.019,
Fig. 4G) but to a greater extent in HEC1A cancer cells (16.7-fold in-
crease, p < 0.0001, Fig. 4G). We also conﬁrmed that BH10 sig-
niﬁcantly decreased the ratio of GSH:GSSG in HEC1A cancer cells, but
not in non-cancerous MAD11 cells (Fig. 4H). Using uniformly labelled
stable isotope 13C-glucose we found that BH10 signiﬁcantly decreased
unlabelled citrate (m0) and increased the production of m2-labelled
citrate in HEC1A cancer cells (Fig. 4I). These results demonstrate that
glucose-derived carbons are the carbon source leading to increased le-
vels of citrate, as opposed to reductive glutamine metabolism. Total
citrate levels in this experiment were increased by 7.4-fold following
90min of BH10 treatment (Fig. 4J), thereby validating the global me-
tabolomics results in Table 1. We next investigated whether citrate
accumulated because of decreased metabolism and found that BH10
caused a signiﬁcant decrease (27.3%, p=0.004) in the activity of
mitochondrial aconitase (Fig. 4K), an enzyme that catalyses the iso-
meration of citrate to isocitrate.
3.5. BH10-induced increases in OCR and cell death are rescued by
antioxidants
Aconitase is a redox-sensitive enzyme inhibited by oxidative da-
mage, therefore we next investigated redox pathways. We ﬁrst ex-
amined cellular oxygen consumption rate (OCR) in BH10-treated non-
cancerous MAD11 cells and HEC1A cancer cells (Fig. 5A). BH10 in-
creased OCR to ~200% in HEC1A cells, but only ~150% in
MAD11 cells (Fig. 5A), suggesting that BH10 had a greater eﬀect on
OCR in cancer cells. Increases in OCR can be indicative of increased
nutrient oxidation and/or increased reactive oxygen species (ROS)
production. To investigate a role for ROS in the mechanism of BH10, we
tested whether antioxidants were able to protect HEC1A cancer cells
from BH10-induced increases in OCR and cell death. Indeed, both N-
acetylcysteine (NAC) and GSH returned the level of OCR back to basal
levels in BH10-treated cells (Fig. 5B) and rescued cells against BH10-
induced cell death (Fig. 5C). These experiments suggest that BH10-in-
duced cell death and increases in OCR are associated with oxidative
stress.
3.6. BH10 perturbs the mitochondrial peroxiredoxin/thioredoxin reductase
system
We next investigated mitochondrial and cytoplasmic oxidative
stress by measuring peroxiredoxin (PRDX) dimerization. PRDX proteins
are involved in the cellular response to oxidative stress and exist in
diﬀerent subcellular compartments [23]. PRDX2 is found in the cyto-
plasm and nucleus, whereas PRDX3 is exclusively in mitochondria [23].
PRDX proteins detoxify hydrogen peroxide (H2O2) to water in a cycling
reaction coupled with thioredoxin (TRX) and thioredoxin reductase,
using NADPH as a primary electron donor [23]. We therefore examined
whether BH10 altered the oxidation (dimerization) of PRDX2 or
PRDX3. BH10 signiﬁcantly increased PRDX3 dimerization, and this
aﬀect was greater in HEC1A cancer cells than MAD11 cells (Fig. 5D).
GSH rescued PRDX3 dimer formation in both cell lines (Fig. 5D). In
contrast, BH10 did not signiﬁcantly alter PRDX2 dimerization (not
shown) suggesting that BH10 may be selectively increasing mitochon-
drial oxidative stress, which is consistent with impaired mitochondrial
aconitase activity (Fig. 4K). We also found that BH10 signiﬁcantly de-
creased the NADPH/NADP+ ratio in HEC1A cancer cells, but not
MAD11 cells (Fig. 5E).
To further explore the eﬀect of BH10 on the PRDX/TRX system, we
exposed cells to auranoﬁn (a thioredoxin reductase inhibitor that im-
pairs mitochondrial antioxidant defence [24]) in combination with
BH10. Results showed that BH10 was highly synergistic (combination
index values less than 1) with a non-toxic dose of auranoﬁn (0.5 μM) in
HEC1A cells. Cell death was induced with lower doses of BH10
(1.25–5 μM) compared with BH10 alone (Fig. 5F). In addition, PRDX3
dimerization was enhanced when BH10 (5 μM) was combined with
Fig. 4. BH10 alters glucose metabolism, and glutathione and citrate levels
in cancer cells. Radiolabelled tracers were used to measure (A) glycolysis
(uniformly-labelled 3H-glucose), (B) glucose oxidation (uniformly-labelled 14C-
glucose), (C) glutamine oxidation (uniformly-labelled 14C-glutamine), (D) pal-
mitate oxidation (uniformly-labelled 14C-palmitate), (E) 1C-glucose oxidation
(1C-labelled 14C-glucose), (F) 6C-glucose oxidation (6C-labelled 14C-glucose),
and (G) Pentose phosphate pathway (PPP) ﬂux (1C-labelled 14C-glucose minus
6C-labelled 14C-glucose), in vehicle (DMSO) and BH10 (20 μM)- treated HEC1A
and MAD11 cells (90 min treatment). (H) Ratio of GSH to GSSG in MAD11 and
HEC1A cells treated with vehicle (DMSO) and BH10 (50 μM, the IC80 when
tested in 15 cm2 plates) (150min treatment). (I) Enrichment of 13C-glucose into
citrate isotopologue in HEC1A cells treated with vehicle (DMSO) and BH10
(50 μM) (90min treatment). (J) Total citrate levels in HEC1A cells treated with
vehicle (DMSO) and BH10 (50 μM) (90min treatment). (K) Mitochondrial
aconitase activity in HEC1A cells treated with vehicle (DMSO) and BH10
(50 μM) (150 min treatment). n ≥ 3 for all experiments. Data from vehicle vs
BH10-treated cells were analysed by unpaired student's t-tests (equal variances)
or Mann-Whitney tests (unequal variances), where alpha = 0.05, *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Data represent mean ± SEM.
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auranoﬁn (0.5 μM), compared to BH10 alone (Fig. 5G). These results
suggest the synergistic cytotoxicity of these 2 drugs may be mediated
through mitochondrial oxidative stress, as indicated by PRDX3 dimer-
ization. In contrast to the results with the HEC1A cancer cells, BH10
had less synergy with auranoﬁn in MAD11 cells (Fig. 5H). In addition,
over-expression of mitochondrial-targeted catalase (an enzyme that
detoxiﬁes H2O2) partially protected cells against BH10-induced toxicity
(Fig. 5I). Together, these data suggest that BH10-mediated cytotoxicity
involves mitochondrial oxidative stress via H2O2.
3.7. Diﬀerences in oxidative stress between BH10 and vitamin K3
To further investigate mechanisms of cancer-selective toxicity, we
compared BH10 to a closely related and well-known anti-cancer qui-
none, vitamin K3. Vitamin K3 is equipotent to BH10 in the context of
cytotoxicity to cancer cells but is not selectively toxic to cancer cells
(Fig. 2C) and increased OCR to greater levels in the non-cancerous cells
(MAD11) than cancer cells (HEC1A) (Fig. 6A). Vitamin K3 was mark-
edly diﬀerent in its redox mechanism as evidenced by decreased total
PRDX2 levels (monomer and dimer) in both cell lines and no eﬀect on
PRDX3 dimerization (Fig. 6B). Since nuclear PRDX2 protects cancer
cells from death and DNA damage [25], we measured 8-hydroxy-2′-
deoxyguanosine levels (an indicator of oxidative DNA damage [26,27])
in cells treated with BH10 and vitamin K3. Results showed that vitamin
K3 signiﬁcantly increased oxidative DNA damage in both MAD11 and
HEC1A cells, whereas BH10 did not (Fig. 6C). Overall, these results
demonstrate distinct mechanisms of oxidative stress between BH10 and
vitamin K3, which may underlie the diﬀerences in cancer-selective
toxicity between these two molecules.
4. Discussion
Phenotypic screens for cancer drug discovery traditionally employ
readouts of intracellular signalling and transcription, cell growth and
death, or ‘classical’ phenotypes such as morphology, motility and dif-
ferentiation [1]. In this study we selected molecules that were bioactive
for increasing cellular oxygen consumption rate and screened them for
cytotoxicity in a panel of cancer and non-cancerous cell lines. This
approach led to the identiﬁcation of the 1,4-Napthoquinone BH10.
1,4-Napthoquinones are known anti-cancer agents and structure-
activity relationship (SAR) studies have reported anti-cancer potency of
naphthoquinones similar to BH10 and including BH10. Brun et al.
synthesized BH10 in an eﬀort to make CDC25 inhibitors [17]. However,
we found that CDC25 phosphatase inhibition is unlikely to be the BH10
mechanism of cytotoxicity because the CDC25 phosphatase inhibitor II
did not have cancer-speciﬁc toxicity (Fig. 2B). Xu et al. also synthesized
BH10 in an eﬀort to make 20S protease inhibitors, but BH10 was not an
eﬀective inhibitor and had minimal eﬀects on proliferation [28]. Hsu
et al. also reported BH10 to be PT-262, which was described as an ERK,
CDC2, and proliferation inhibitor [29] but an erratum later showed that
PT-262 was a diﬀerent molecule [30]. Although BH10 has been studied
previously in the context of cancer, none of these studies compared the
cytotoxicity of BH10 to cancer and non-cancerous cells, or identiﬁed
mechanisms related to oxidative stress, mitochondria, or metabolism.
In this study, we enlisted a comprehensive set of metabolic studies
which showed that treatment of cancer cells with BH10; 1) rapidly
increased oxygen consumption rate, higher than that of non-cancerous
cells, 2) increased glucose ﬂux through the PPP, higher than in non-
cancerous cells, 3) increased glucose ﬂux into mitochondria and TCA
cycle, and 4) increased citrate levels. This was coupled with a sig-
niﬁcant decrease in GSH:GSSG and NAPDH/NAPD+ ratios only in
cancer cells and glycolysis/glycolytic intermediates. It is possible that
the alterations in metabolism are secondary to oxidative stress occur-
ring in mitochondria. For example, BH10 treatment led to a marked
increase in citrate levels (~7-fold) that may be attributed to a decrease
in the activity of mitochondrial aconitase; an enzyme that converts ci-
trate to isocitrate, and is sensitive to oxidative stress and decreased GSH
levels [31,32]. Citrate may be responsible for the decrease in glycolysis
via allosteric inhibition of the rate-limiting glycolytic enzyme phos-
phofructokinase [33], which is supported by metabolomics data
showing signiﬁcant decreases in metabolites downstream of fructose-6-
phosphate in BH10-treated cancer cells. The interconnection of these
Fig. 5. BH10 increases mitochondrial oxidative stress. (A) Oxygen con-
sumption rate (OCR) presented as a percentage of basal readings in MAD11 and
HEC1A cells treated with vehicle (DMSO) or BH10 (20 μM). Injection of vehicle
and BH10 indicated by arrow. (B) OCR presented as a percentage of basal
readings in HEC1A cells treated with vehicle (DMSO) or BH10 (20 μM), fol-
lowed by NAC or GSH (2mM each). Injection of vehicle and BH10, or NAC or
GSH, indicated by arrows. (C) Viability (%, normalised to vehicle control) of
HEC1A cells treated with vehicle (DMSO) or BH10 (20 μM), alone or in com-
bination with antioxidants NAC or GSH (2mM each) for 48 h. (D)
Representative western blot of peroxiredoxin 3 (PRDX3) dimerization in
MAD11 and HEC1A cells treated with vehicle (DMSO), BH10 (BH10, 20 μM), or
BH10 (BH10) in combination with GSH (150min treatment). 14-3-3 serves as a
protein loading control. Graph shows quantiﬁcation of PRDX3 dimer to
monomer (band densitometry) ratio for each condition shown in western blot.
Viability (%, normalised to vehicle control) of HEC1A (F) and MAD11 (H) cells
treated with BH10 alone or in combination with 0.5 μM auranoﬁn. Synergy is
indicated when combination index (CI) values are less than 1. (G)
Representative western blot of peroxiredoxin 3 (PRDX3) dimerization in HEC1A
cells treated with vehicle (Veh), BH10 (5 μM), BH10 (5 μM) in combination
with auranoﬁn (0.5 μM) (BH10 + Aura), or auranoﬁn (0.5 μM) alone (Aura) for
150 min 14-3-3 serves as a protein loading control. Graph shows quantiﬁcation
of PRDX3 dimer to monomer (band densitometry) ratio for each condition
shown in western blot. (I) Viability (%, normalised to vehicle control) of 3T3-L1
cells expressing mitochondrial catalase (mCAT) or empty vector (EV), treated
with vehicle (DMSO) or BH10 (μM) for 48 h n ≥ 3 for all experiments. Data
were analysed by 2-way ANOVA (D, F–I) and 1-way ANOVA (E), with multiple
comparison tests, where alpha = 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001, ns = not signiﬁcant. Data represent mean ± SEM.
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pathways is illustrated in the Graphical Abstract.
A BH10-mediated mitochondrial oxidative stress mechanism of
cancer cell death is also supported by protection induced by mi-
tochondria-targeted catalase and selective increases in PRDX3 oxida-
tion in mitochondria. Furthermore, impairment of mitochondrial oxi-
dative stress defence (with auranoﬁn) demonstrated strong cytotoxic
synergy with BH10 (Fig. 5F), which was associated with an increase in
PRDX3 dimerization. These results point to a mitochondrial oxidative
stress mechanism via increased H2O2 and activation of the mitochon-
drial peroxiredoxin/thioredoxin reductase system.
It is well established that ROS are elevated in cancer cells and, as an
adaptive response, have higher levels of ROS-scavenging molecules
such as GSH [34]. Consistent with this, we observed higher GSH:GSSG
and NADPH/NADP+ ratios in cancer cells than normal cells (Figs. 4H
and 5E). GSH and NADPH are intricately linked, since NADPH is re-
quired for the conversion of GSSG to GSH via GSH reductase. This
feature of cancer cells could explain why we observed signiﬁcant de-
creases in both GSH:GSSG and NADPH/NADP + ratios in cancer cells
upon exposure to BH10, but not in normal cells. Thus, higher levels of
PRDX3 oxidation in cancer cells, coupled with signiﬁcant decreases in
GSH and NADPH speciﬁcally in cancer cells, may underlie cell death
and selective toxicity to cancer cells. These results support the hy-
pothesis that cancer cells may be more susceptible to the eﬀects of
oxidative stress than normal cells [10].
Perturbations in cell metabolism can induce cell death via diﬀerent
mechanisms, including apoptosis, necroptosis, ferroptosis and necrosis
[35]. We found that BH10 did not induce caspase activity or PARP
cleavage; indicating that cell death was not occurring via apoptosis.
Inhibitors of necroptosis and ferroptosis also did not protect cancer cells
from BH10-induced death, eliminating these pathways as potential
mechanisms. These results point to a necrotic mechanism of cell death.
In support of this, our metabolomics data showed BH10 treatment
signiﬁcantly decreased NAD+ and lactate levels at the 150-min time
point prior to cell death. NAD+ is produced when pyruvate is converted
to lactate by lactate dehydrogenase, and is an important substrate for
PARP-mediated apoptosis [35]. BH10 treatment also signiﬁcantly de-
creased ADP and ADP-ribose, while ribose was signiﬁcantly increased,
suggesting that BH10 treatment may disrupt poly(ADP-ribose) synthesis
and/or degradation pathways required for apoptotic cell death. Inter-
estingly, previous studies have shown that the synergistic cytotoxicity
of β-lapachone combined with PARP inhibitors leads to tumour-selec-
tive apoptosis and is mediated via NQO1-dependent redox cycling [36].
In contrast, our results show that BH10 is not synergistic with the PARP
inhibitor, olaparib. Furthermore, unlike β-lapachone, we propose that
NQO1 is not involved in mediating BH10-induced cytotoxicity since the
NQO1 inhibitor, ES936, did not protect against BH10-induced cell
death (not shown). Another point of diﬀerence between these two
quinones is that BH10 increases [U–13C]-glucose incorporation into m
+2 citrate, while the opposite occurs for β-lapachone in an NQO1-
dependent manner [37]. These results highlight diﬀerent mechanisms
of action and cell death between these quinones, which may underlie
the diﬀerences in cytotoxicity between BH10 and β-lapachone in cancer
vs non-cancer cells this study.
Diﬀerences in cancer cell selective toxicity between BH10 and other
quinones, such vitamin K3, indicate BH10 has a distinct mechanism of
action to these molecules. Examination of oxidative stress markers be-
tween vitamin K3 and BH10 showed that BH10 increased mitochon-
drial PRDX3 oxidation to higher levels in cancer cells, whereas vitamin
K3 decreased PRDX2 abundance and induced oxidative DNA damage in
both cancer and non-cancerous cells. These results suggest that BH10
and vitamin K3 induce oxidative stress in diﬀerent subcellular loca-
tions, which may underpin their diﬀerences in cytotoxicity between
cancer and non-cancerous cells. Further development of quinones as
anti-cancer agents may be able to exploit this phenotype to improve
cancer cell selective toxicity and decrease unwanted side eﬀects.
5. Conclusion
Our phenotypic screen identiﬁed a 1,4-Naphthoquinone molecule
(BH10) that has a unique mechanism of action and improved cancer-
selective toxicity compared to other anti-cancer quinones, piperlongu-
mine, and molecules that target glucose metabolism. Metabolic pro-
ﬁling revealed that BH10 targets multiple metabolic pathways that are
often considered ‘hallmarks’ of cancer [5]. Indeed, BH10 reversed as-
pects of cancer metabolism by decreasing glycolysis while simulta-
neously increasing glucose oxidation via mitochondrial and pentose
Fig. 6. Diﬀerences in oxidative stress
between BH10 and vitamin K3. (A)
Oxygen consumption rate (OCR) presented
as a percentage of basal readings in MAD11
and HEC1A cells treated with vehicle
(DMSO) or vitamin K3 (VitK3, 20 μM).
Injection of vehicle and VitK3 indicated by
arrow. (B) Representative western blots of
peroxiredoxin 2 (PRDX2) and 3 (PRDX3) in
MAD11 and HEC1A cells treated with ve-
hicle (DMSO) and VitK3 (VK3, 20 μM)
(150min treatment). 14-3-3 serves as a
protein loading control. (C) Oxidative DNA
damage assay (measuring 8-hydroxy-2′-
deoxyguanosine) performed on MAD11 and
HEC1A cells treated with vehicle (DMSO),
BH10 (20 μM) or VitK3 (20 μM) for 6 h.
Data were analysed by 1-way ANOVA (C)
with multiple comparison tests, where
alpha = 0.05, *p ≤ 0.05, ***p ≤ 0.001,
ns = not signiﬁcant. Data in A and C re-
present mean ± SEM.
F.L. Byrne, et al. Redox Biology 28 (2020) 101374
9
phosphate pathways. BH10 disrupted redox balance in mitochondria
without inducing cytoplasmic PRDX2 oxidation or causing nuclear DNA
oxidative damage.
While it is clear that mitochondrial oxidative stress is involved in
the mechanism linking BH10 to cancer cell death, a limitation of this
study is that the mechanism, or mechanisms, of BH10-mediated mi-
tochondrial redox regulation remains unclear. Future studies are re-
quired to identify BH10 targets and molecular marker/s that predict
sensitivity to this molecule. Proteomics-based BH10-pulldown studies
were unable to validate a speciﬁc interaction (not shown) and we
cannot exclude other possibilities including that BH10 is redox cycled
by a mitochondrial enzyme. However, this study demonstrates the po-
tential of phenotypic drug screens employing oxygen consumption rate
as a gain-of-function primary readout for the discovery of novel anti-
cancer agents.
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